Unknown

Dataset Information

0

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

ABSTRACT: Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.

SUBMITTER: Shiramizu B 

PROVIDER: S-EPMC4503484 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

Shiramizu Bruce B   Goldman Stanton S   Smith Lynette L   Agsalda-Garcia Melissa M   Galardy Paul P   Perkins Sherrie L SL   Frazer J Kimble JK   Sanger Warren W   Anderson James R JR   Gross Thomas G TG   Weinstein Howard H   Harrison Lauren L   Barth Matthew J MJ   Mussolin Lara L   Cairo Mitchell S MS  

British journal of haematology 20150408 3

Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease r  ...[more]

Similar Datasets

Unknown Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
| S-EPMC4198418 | biostudies-literature
Unknown Minimal residual disease in acute myeloid leukaemia.
| S-EPMC4163748 | biostudies-literature
Unknown Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
| S-EPMC4543229 | biostudies-literature
Unknown Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
| S-EPMC3325039 | biostudies-literature
Unknown Quiescent leukaemic cells account for minimal residual disease in childhood lymphoblastic leukaemia.
| S-EPMC4693965 | biostudies-literature
Unknown Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.
| S-EPMC2265447 | biostudies-literature
Unknown Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
| S-EPMC2424148 | biostudies-literature
Unknown Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia.
| S-EPMC6838385 | biostudies-literature
Unknown Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
| S-EPMC5351601 | biostudies-literature
Unknown Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
| S-EPMC8480280 | biostudies-literature